NKGEN BIOTECH Stock Forum

$NKGEN BIOTECH (NKGN.US)$
NKGen Biotech Presents Phase 1/2a Troculeucel Data in Alzheimer’s Disease at the 17th Annual Clinical Trials on Alzheimer’s Disease (CTAD) Conference
NKGen Biotech presented Phase 1/2a trial data for troculeucel in Alzheimer's Disease at the CTAD Conference. The Phase 1 trial showed that troculeucel reduces several biomarkers detectable up to 10 years before dementia symptoms. In the Phase 1/2a trial, using the highest dose of 6 billion cells, all three treated sub...

Needs to hold .3356 for a curl back up. Here are the levels to watch.
Larger Image: tradingview.com...
$NKGEN BIOTECH (NKGN.US)$  

$NKGEN BIOTECH (NKGN.US)$ 🚀

$NKGEN BIOTECH (NKGN.US)$ coming

$Werewolf Therapeutics (HOWL.US)$ $Shoals Technologies (SHLS.US)$ $NKGEN BIOTECH (NKGN.US)$ $LogicMark (LGMK.US)$ $Aditxt (ADTX.US)$ $Aptevo Therapeutics (APVO.US)$ $VSee Health (VSEE.US)$ $Genprex (GNPX.US)$ $Spirit Airlines (SAVE.US)$ $BioVie (BIVI.US)$ $Expion360 (XPON.US)$ $GRI Bio (GRI.US)$
📊⚡️📊

$NKGEN BIOTECH (NKGN.US)$
NKGen Biotech Announces Poster Presentations at the 17th Annual Clinical Trials on Alzheimer’s Disease (CTAD) Conference
NKGen Biotech Inc. (Nasdaq: NKGN) announced upcoming poster presentations at the 17th Annual Clinical Trials on Alzheimer's Disease Conference (CTAD) in Madrid, Spain from October 29 – November 1, 2024. The presentations will cover:
1. A final report of a Phase 1 dose escalation study and a preliminary report of the Phase 1 cohort in the follow-up ...